TNFSF10 and Alzheimer disease: In the present study, we investigated the ability of a TRAIL neutralizing monoclonal antibody adsorbed onto the surface of PLGA and NLC NPs to reach the brain through the nose-to-brain (N2B) route, to obtain more effective drug delivery systems suitable for the treatment of neurodegenerative disorders, such as AD.